180 Life Sciences Corp. (NASDAQ: ATNF) — FY 2023 Form 10-K
Filing identity: The supplied filing is for 180 Life Sciences Corp., not FORUM MARKETS Inc. It covers the fiscal year ended December 31, 2023; it does not provide standalone fourth-quarter results. Financial statements reflect the February 2024 1-for-19 reverse split retroactively.
Business context and reporting period
180 Life Sciences is a clinical-stage biotechnology company developing treatments for fibrosis, inflammation and chronic pain. Its main clinical program is local adalimumab treatment for early-stage Dupuytren’s contracture. CBD-analog research remains preclinical, and the α7nAChR program is suspended for lack of resources. The company reports no product revenue and does not expect near-term revenue.
Financial performance and liquidity
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $2.30 million | $2.19 million |
| General and administrative expense | $10.65 million | $15.46 million |
| Operating loss | $13.48 million | $17.90 million |
| Net loss | $19.94 million | $38.73 million |
| Net cash used in operations | $10.92 million | $12.13 million |
| Cash provided by financing | $5.91 million | $10.87 million |
| Cash at year-end | $1.98 million | $6.97 million |
At December 31, 2023, total assets were $5.26 million and total liabilities were $5.39 million, producing a stockholders’ deficit of $127,733 and a working-capital deficit of $1.42 million. Loans payable totaled approximately $1.05 million, including $1.03 million current. The filing reports approximately $0.8 million cash on hand as of March 18, 2024 and estimates that cash would fund planned operations only through approximately May 2024. Monthly cash requirements were estimated at about $350,000. There is no clear standalone quarterly cash-flow or margin figure; with no revenue, conventional revenue margins are not meaningful.
The lower FY 2023 net loss chiefly reflects the absence of FY 2022’s $33.55 million goodwill impairment and a much smaller noncash gain from changes in derivative fair value. FY 2023 included a $9.06 million impairment of in-process R&D assets, eliminating their remaining balance, partly offset in the tax line by a $2.35 million income-tax benefit. G&A fell 31%, mainly due to lower legal, insurance, bonus and stock-compensation expenses. Operating cash use declined modestly, but year-end cash fell by $4.99 million.
Material developments, outlook and risks
- Clinical and regulatory: The Dupuytren’s Phase 2b trial reported statistically significant improvement in nodule hardness and size, with no related severe adverse events. The UK MHRA said Phase 2b evidence was insufficient for conditional authorization and requires a Phase 3 study before considering marketing authorization; it indicated one Phase 3 study could potentially suffice if convincing efficacy and safety are demonstrated. The company says the study depends on obtaining funding. FDA discussions and a biosimilar supplier arrangement remain unresolved.
- Other programs: Frozen-shoulder feasibility recruitment ended at nine participants after a UK request to close a slow-recruiting trial; another trial may be needed. The HMGB1 Oxford license was terminated in September 2023, and the α7nAChR program remains suspended. A planned Phase 2 POCD study was discussed for 2024, but the filing does not establish that it began.
- Funding and going concern: The auditor issued an unmodified opinion but included a going-concern explanatory paragraph, citing losses, working-capital deficiency and the need for additional financing. Management states substantial doubt exists about continuing as a going concern. Further equity, debt, licensing or collaboration financing may be unavailable or dilutive; the filing warns operations may need to be curtailed and bankruptcy protection could become necessary.
- Oxford obligations: Oxford alleges approximately £929,030 is owed under licenses and agreements. Discussions toward a reduced amount or payment plan had not produced definitive terms in the filing. Oxford had engaged counsel to collect the amounts with interest and threatened legal action; the company warns of possible license termination or action affecting a UK subsidiary.
- Strategic review and governance: In December 2023, the company retained A.G.P./Alliance Global Partners to evaluate strategic alternatives, including a merger, asset sale or licensing transaction. No outcome is assured. All independent directors resigned in December 2023 over cost-cutting differences; new directors were appointed in February and March 2024, after the reporting date.
- Nasdaq: Nasdaq closed the minimum-bid-price deficiency after the February 2024 reverse split and March 2024 recovery of the $1 bid threshold. The separate stockholders’ equity deficiency remained unresolved in the filing: Nasdaq had granted an extension requiring the company to demonstrate at least $2.5 million equity by May 13, 2024, with possible delisting if it failed to establish compliance. The company also reported that the August 2023 offering-related shareholder-approval deficiency was closed in December 2023; warrant issuance approval was subsequently obtained in February 2024.
- Accounting, legal and other items: Management concluded disclosure controls and internal control over financial reporting were effective at year-end and said a previously reported material weakness had been remediated; the auditor was not engaged to audit internal controls. The company is pursuing or defending several legacy disputes, including an insurance-coverage case; a February 2024 interim order required insurers to advance certain defense costs, but final liability and reimbursement remain uncertain. No material cybersecurity incident was reported for 2023.
Most important facts for investors to verify
- Current cash, burn rate, financing availability and whether the company has adequate liquidity beyond the stated May 2024 runway.
- Whether the Nasdaq stockholders’ equity deficiency was cured by the May 13, 2024 deadline, and the company’s current listing status.
- Oxford’s final claimed balance, any executed payment plan, and whether licenses or subsidiary operations are at risk.
- Funding, supplier terms, regulatory feedback and a credible timetable and budget for the required Dupuytren’s Phase 3 trial.
- Current capitalization and dilution exposure from outstanding warrants, options, equity-plan capacity and future financing.
- Progress and potential outcomes of the strategic review and material litigation, including the insurance case.